BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Divarasib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Divarasib\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04302025-2217@assetmemo.bio
DTSTAMP:20261121T004541Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Divarasib: Phase 2 readout est. (NCT04302025)
DESCRIPTION:Divarasib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Stu
 dy of Multiple Therapies in Biomarker-selected Participants With Resectabl
 e Stages IB-III Non-small Cell Lung Cancer (NSCLC)\nEstimated primary comp
 letion: 30 November 2026. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/divarasib#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT04302025
URL:https://assetmemo.bio/drug/divarasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03178552-2217@assetmemo.bio
DTSTAMP:20261121T004541Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Divarasib: Phase 2/3 readout est. (NCT03178552)
DESCRIPTION:Divarasib\, phase 2/3\, Non-Small Cell Lung Cancer.\nStudy: A S
 tudy to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as
  Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)\nEsti
 mated primary completion: 30 June 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/divarasib#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT03178552
URL:https://assetmemo.bio/drug/divarasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04449874-2217@assetmemo.bio
DTSTAMP:20261121T004541Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Divarasib: Phase 1 readout est. (NCT04449874)
DESCRIPTION:Divarasib\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: A Stu
 dy to Evaluate the Safety\, Pharmacokinetics\, and Activity of GDC-6036 Al
 one or in Combination in Participants With Advanced or Metastatic Solid Tu
 mors With a KRAS G12C Mutation\nEstimated primary completion: 31 December 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/divarasib#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT04449874
URL:https://assetmemo.bio/drug/divarasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06793215-2217@assetmemo.bio
DTSTAMP:20261121T004541Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Divarasib: Phase 3 readout est. (NCT06793215)
DESCRIPTION:Divarasib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A Stu
 dy Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versu
 s Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participant
 s With Previously Untreated\, KRAS G12C-Mutated\, Advanced or Metastatic N
 on-Squamous Non-Small Cell Lung Cancer\nEstimated primary completion: 30 N
 ovember 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/divaras
 ib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6793215
URL:https://assetmemo.bio/drug/divarasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04929223-2217@assetmemo.bio
DTSTAMP:20261121T004541Z
DTSTART;VALUE=DATE:20300831
DTEND;VALUE=DATE:20300901
SUMMARY:Divarasib: Phase 1 readout est. (NCT04929223)
DESCRIPTION:Divarasib\, phase 1.\nStudy: A Study Evaluating the Safety and 
 Efficacy of Targeted Therapies in Subpopulations of Patients With Metastat
 ic Colorectal Cancer (INTRINSIC)\nEstimated primary completion: 31 August 
 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/divarasib#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT04929223
URL:https://assetmemo.bio/drug/divarasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05789082-2217@assetmemo.bio
DTSTAMP:20261121T004541Z
DTSTART;VALUE=DATE:20320129
DTEND;VALUE=DATE:20320130
SUMMARY:Divarasib: Phase 1/2 readout est. (NCT05789082)
DESCRIPTION:Divarasib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A S
 tudy Evaluating the Safety\, Activity\, and Pharmacokinetics of Divarasib 
 as a Single Agent or in Combination With Other Anti-Cancer Therapies in Pa
 rticipants With Previously Untreated Advanced or Metastatic Non-Small Cell
  Lung Cancer With a KRAS G12C Mutation\nEstimated primary completion: 29 J
 anuary 2032. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/divarasi
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05
 789082
URL:https://assetmemo.bio/drug/divarasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07541170-2217@assetmemo.bio
DTSTAMP:20261121T004541Z
DTSTART;VALUE=DATE:20320131
DTEND;VALUE=DATE:20320201
SUMMARY:Divarasib: Phase 3 readout est. (NCT07541170)
DESCRIPTION:Divarasib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A Stu
 dy to Evaluate the Efficacy and Safety of Divarasib Compared With Investig
 ator's Choice of Immunotherapy or Observation in Participants With Resecte
 d Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)\nEsti
 mated primary completion: 31 January 2032. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/divarasib#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07541170
URL:https://assetmemo.bio/drug/divarasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04589845-2217@assetmemo.bio
DTSTAMP:20261121T004541Z
DTSTART;VALUE=DATE:20320925
DTEND;VALUE=DATE:20320926
SUMMARY:Divarasib: Phase 2 readout est. (NCT04589845)
DESCRIPTION:Divarasib\, phase 2.\nStudy: Tumor-agnostic Precision Immuno-on
 cology and Somatic Targeting Rational for You (TAPISTRY) Platform Study\nE
 stimated primary completion: 25 September 2032. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/divarasib#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT04589845
URL:https://assetmemo.bio/drug/divarasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05862285-2217@assetmemo.bio
DTSTAMP:20261121T004541Z
DTSTART;VALUE=DATE:20330301
DTEND;VALUE=DATE:20330302
SUMMARY:Divarasib: Phase 3 readout est. (NCT05862285)
DESCRIPTION:Divarasib\, phase 3.\nStudy: A Rollover Study for Participants 
 Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored St
 udy\nEstimated primary completion: 1 March 2033. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/divarasib#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT05862285
URL:https://assetmemo.bio/drug/divarasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
